Pandemic H5N1 Influenza
4
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Adjuvanted H5n1 Pandemic Influenza Vaccine
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
Research Network
Common Treatments
- Adjuvanted H5n1 Pandemic Influenza Vaccine3
- H5n1 Pandemic Influenza Vaccine 375µg1
- H5n1 Pandemic Influenza Vaccine 75µg1
Active Sponsors
- Novartis Vaccines4
- Department of Health and Human Services3
Top Investigators
Novartis Vaccines